MedPageToday -- MILAN -- Final results of the IRESSA Ran Asia Study (IPASS) failed to show any difference in overall survival between patients with advanced non-small cell lung cancer treated with gefitinib (Iressa) or carboplatin (Paraplatin) and paclitaxel (Taxol) chemotherapy, researchers said here.
